Cargando…

Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas

Primary spinal cord tumors contribute to ≤ 10% of central nervous system tumors in individuals of pediatric or adolescent age. Among intramedullary tumors, spinal ependymomas make up ~ 30% of this rare tumor population. A twelve-year-old male presented with an intradural, extramedullary mass occupyi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shatara, Margaret, Schieffer, Kathleen M., Klawinski, Darren, Thomas, Diana L., Pierson, Christopher R., Sribnick, Eric A., Jones, Jeremy, Rodriguez, Diana P., Deeg, Carol, Hamelberg, Elizabeth, LaHaye, Stephanie, Miller, Katherine E., Fitch, James, Kelly, Benjamin, Leraas, Kristen, Pfau, Ruthann, White, Peter, Magrini, Vincent, Wilson, Richard K., Mardis, Elaine R., Abdelbaki, Mohamed S., Finlay, Jonathan L., Boué, Daniel R., Cottrell, Catherine E., Ghasemi, David R., Pajtler, Kristian W., Osorio, Diana S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665631/
https://www.ncbi.nlm.nih.gov/pubmed/34895332
http://dx.doi.org/10.1186/s40478-021-01296-2
_version_ 1784614049381613568
author Shatara, Margaret
Schieffer, Kathleen M.
Klawinski, Darren
Thomas, Diana L.
Pierson, Christopher R.
Sribnick, Eric A.
Jones, Jeremy
Rodriguez, Diana P.
Deeg, Carol
Hamelberg, Elizabeth
LaHaye, Stephanie
Miller, Katherine E.
Fitch, James
Kelly, Benjamin
Leraas, Kristen
Pfau, Ruthann
White, Peter
Magrini, Vincent
Wilson, Richard K.
Mardis, Elaine R.
Abdelbaki, Mohamed S.
Finlay, Jonathan L.
Boué, Daniel R.
Cottrell, Catherine E.
Ghasemi, David R.
Pajtler, Kristian W.
Osorio, Diana S.
author_facet Shatara, Margaret
Schieffer, Kathleen M.
Klawinski, Darren
Thomas, Diana L.
Pierson, Christopher R.
Sribnick, Eric A.
Jones, Jeremy
Rodriguez, Diana P.
Deeg, Carol
Hamelberg, Elizabeth
LaHaye, Stephanie
Miller, Katherine E.
Fitch, James
Kelly, Benjamin
Leraas, Kristen
Pfau, Ruthann
White, Peter
Magrini, Vincent
Wilson, Richard K.
Mardis, Elaine R.
Abdelbaki, Mohamed S.
Finlay, Jonathan L.
Boué, Daniel R.
Cottrell, Catherine E.
Ghasemi, David R.
Pajtler, Kristian W.
Osorio, Diana S.
author_sort Shatara, Margaret
collection PubMed
description Primary spinal cord tumors contribute to ≤ 10% of central nervous system tumors in individuals of pediatric or adolescent age. Among intramedullary tumors, spinal ependymomas make up ~ 30% of this rare tumor population. A twelve-year-old male presented with an intradural, extramedullary mass occupying the dorsal spinal canal from C6 through T2. Gross total resection and histopathology revealed a World Health Organization (WHO) grade 2 ependymoma. He recurred eleven months later with extension from C2 through T1-T2. Subtotal resection was achieved followed by focal proton beam irradiation and chemotherapy. Histopathology was consistent with WHO grade 3 ependymoma. Molecular profiling of the primary and recurrent tumors revealed a novel amplification of the MYC (8q24) gene, which was confirmed by fluorescence in situ hybridization studies. Although MYC amplification in spinal ependymoma is exceedingly rare, a newly described classification of spinal ependymoma harboring MYCN (2p24) amplification (SP-MYCN) has been defined by DNA methylation-array based profiling. These individuals typically present with a malignant progression and dismal outcomes, contrary to the universally excellent survival outcomes seen in other spinal ependymomas. DNA methylation array-based classification confidently classified this tumor as SP-MYCN ependymoma. Notably, among the cohort of 52 tumors comprising the SP-MYCN methylation class, none harbor MYC amplification, highlighting the rarity of this genomic amplification in spinal ependymoma. A literature review comparing our individual to reported SP-MYCN tumors (n = 26) revealed similarities in clinical, histopathologic, and molecular features. Thus, we provide evidence from a single case to support the inclusion of MYC amplified spinal ependymoma within the molecular subgroup of SP-MYCN. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-021-01296-2.
format Online
Article
Text
id pubmed-8665631
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86656312021-12-13 Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas Shatara, Margaret Schieffer, Kathleen M. Klawinski, Darren Thomas, Diana L. Pierson, Christopher R. Sribnick, Eric A. Jones, Jeremy Rodriguez, Diana P. Deeg, Carol Hamelberg, Elizabeth LaHaye, Stephanie Miller, Katherine E. Fitch, James Kelly, Benjamin Leraas, Kristen Pfau, Ruthann White, Peter Magrini, Vincent Wilson, Richard K. Mardis, Elaine R. Abdelbaki, Mohamed S. Finlay, Jonathan L. Boué, Daniel R. Cottrell, Catherine E. Ghasemi, David R. Pajtler, Kristian W. Osorio, Diana S. Acta Neuropathol Commun Case Report Primary spinal cord tumors contribute to ≤ 10% of central nervous system tumors in individuals of pediatric or adolescent age. Among intramedullary tumors, spinal ependymomas make up ~ 30% of this rare tumor population. A twelve-year-old male presented with an intradural, extramedullary mass occupying the dorsal spinal canal from C6 through T2. Gross total resection and histopathology revealed a World Health Organization (WHO) grade 2 ependymoma. He recurred eleven months later with extension from C2 through T1-T2. Subtotal resection was achieved followed by focal proton beam irradiation and chemotherapy. Histopathology was consistent with WHO grade 3 ependymoma. Molecular profiling of the primary and recurrent tumors revealed a novel amplification of the MYC (8q24) gene, which was confirmed by fluorescence in situ hybridization studies. Although MYC amplification in spinal ependymoma is exceedingly rare, a newly described classification of spinal ependymoma harboring MYCN (2p24) amplification (SP-MYCN) has been defined by DNA methylation-array based profiling. These individuals typically present with a malignant progression and dismal outcomes, contrary to the universally excellent survival outcomes seen in other spinal ependymomas. DNA methylation array-based classification confidently classified this tumor as SP-MYCN ependymoma. Notably, among the cohort of 52 tumors comprising the SP-MYCN methylation class, none harbor MYC amplification, highlighting the rarity of this genomic amplification in spinal ependymoma. A literature review comparing our individual to reported SP-MYCN tumors (n = 26) revealed similarities in clinical, histopathologic, and molecular features. Thus, we provide evidence from a single case to support the inclusion of MYC amplified spinal ependymoma within the molecular subgroup of SP-MYCN. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-021-01296-2. BioMed Central 2021-12-11 /pmc/articles/PMC8665631/ /pubmed/34895332 http://dx.doi.org/10.1186/s40478-021-01296-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Shatara, Margaret
Schieffer, Kathleen M.
Klawinski, Darren
Thomas, Diana L.
Pierson, Christopher R.
Sribnick, Eric A.
Jones, Jeremy
Rodriguez, Diana P.
Deeg, Carol
Hamelberg, Elizabeth
LaHaye, Stephanie
Miller, Katherine E.
Fitch, James
Kelly, Benjamin
Leraas, Kristen
Pfau, Ruthann
White, Peter
Magrini, Vincent
Wilson, Richard K.
Mardis, Elaine R.
Abdelbaki, Mohamed S.
Finlay, Jonathan L.
Boué, Daniel R.
Cottrell, Catherine E.
Ghasemi, David R.
Pajtler, Kristian W.
Osorio, Diana S.
Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas
title Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas
title_full Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas
title_fullStr Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas
title_full_unstemmed Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas
title_short Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas
title_sort clinically aggressive pediatric spinal ependymoma with novel myc amplification demonstrates molecular and histopathologic similarity to newly described mycn-amplified spinal ependymomas
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665631/
https://www.ncbi.nlm.nih.gov/pubmed/34895332
http://dx.doi.org/10.1186/s40478-021-01296-2
work_keys_str_mv AT shataramargaret clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT schiefferkathleenm clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT klawinskidarren clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT thomasdianal clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT piersonchristopherr clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT sribnickerica clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT jonesjeremy clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT rodriguezdianap clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT deegcarol clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT hamelbergelizabeth clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT lahayestephanie clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT millerkatherinee clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT fitchjames clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT kellybenjamin clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT leraaskristen clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT pfauruthann clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT whitepeter clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT magrinivincent clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT wilsonrichardk clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT mardiselainer clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT abdelbakimohameds clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT finlayjonathanl clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT bouedanielr clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT cottrellcatherinee clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT ghasemidavidr clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT pajtlerkristianw clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas
AT osoriodianas clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas